Combination for Cyclophosphamide (NSC-26271), Vincristine (NSC-67574) and 5-Fluorouracil (NSC-19893) in the Treatment of Advanced Breast Cancer

Prediction Of Early Mortality With Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients From MRC/NCRI and SWOG

X Wang;I Thomas;C Ariti;M Dennis;P Mehta;N Russell;M Sydenham;R Hills;A Burnett;S Nand;S Assouline;L Michaelis;H Erba;K Kerr;R Walter;M Othus American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #220

Bias in mean survival from fitting cure models with limited follow-up

M Othus;A Bansal;H Erba;S Ramsey Value in Health Aug;23(8):1034-1039

PMid: PMID32828215 | PMC number: PMC7446760

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: An analysis of four SWOG studies

M Othus;M Sekeres;S Nand;G Garcia-Manero;F Appelbaum;HP Erba;E Estey Leukemia Feb;33(2):371-378; Oct 12. doi: 10.1038/s41375-018-0275-x. [Epub ahead of print]

PMid: PMID30315234 | PMC number: PMC6367029

Allogeneic Hematopoietic Cell Transplantation Compared to Chemotherapy Consolidation in older Acute Myeloid Leukemia (AML) Patients 60-75 Years in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

C Ustun;J Le-Rademacher;H-L Wang;M Othus;Z Sun;B Major;M-J Zhang;E Storrick;J Lafky;S Chow;K Mrozek;E Attar;C Bloomfield;L Cripe;M Tallman;F Appelbaum;S Nand;R Larson;G Marcucci;G Roboz;GL Uy;RM Stone;A Jatoi;T Shea;M di Lima;J Foran;B Sandmaier;M Litzow;H Erba;A Hurria;D Weisdorf;A Artz Leukemia Nov;33(11):2599-2609

PMid: PMID31073153 | PMC number: PMC6842042

Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies

A Statler;M Othus;H Erba;T Chauncey;J Radich;S Coutre;A Advani;S Nand;F Ravandi;S Mukherjee;M Sekeres Blood Jun 21;131(25):2782-2788; Apr 4 [Epub ahead of print]

PMid: PMID29618479 | PMC number: PMC6014358

Association between early DNA methylation changes and outcome in older patients with acute myeloid leukemia treated on SWOG S0703

N Achille;M Othus;K Phelan;S Zhang;K Cooper;J Godwin;F Appelbaum;J Radich;H Erba;S Nand;N Zeleznik-Le Leukemia Research Mar;42:68-74

PMid: PMID26818573 | PMC number: PMC4779662

Relation between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVN/SAKK, and MRC/NCRI

M Othus;W van Putten;B Lowenberg;S Petersdorf;S Nand;H Erba;F Appelbaum;R Hills;N Russell;A Burnett;E Estey Haematologica Jul;101(7):e284-286; 2016 Mar 24 [Epub ahead of print]

PMid: PMID27013652 | PMC number: PMC5004473

Complete remissions (CRs) with azacitidine regimens compared to CRs with 7+3 induction chemotherapy and the effect on overall survival

M Othus;M Sekeres;S Nand;G Garcia-Manero;F Appelbaum;H Erba;E Estey Blood 128:1613; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster

Comparable outcomes of patients eligible versus ineligible for SWOG leukemia studies

A Statler;M Othus;H Erba;T Chauncey;J Radich;S Coutre;A Advani;S Nand;F Ravandi;S Mukherjee;M Sekeres Blood 128:4002; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT00658814)

S Nand;N Achille;M Othus;K Phelan;S Zhang;K Cooper;J Godwin;F Appelbaum;J Radich;H Erba;N Zeleznik-Le Journal of Clinical Oncology J Clin Oncol 33:5s (suppl; abstr 7060); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster;

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

S Nand;M Othus;JE Godwin;CL Willman;TH Norwood;DS Howard;SE Coutre;HP Erba;FR Appelbaum Blood 122(20):3432-3439;

PMid: PMID24092933 | PMC number: PMC3829116

Alteration of cytogenetic risk stratification in new diagnosis of leukemia by FISH testing - the SWOG experience

M Fang;S McDonough;M Othus;L Zhuo;D Roulston;H Erba;F Appelbaum Blood 122:1383; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster;

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report on the Good Risk Patients

S Nand;H Gundacker;JE Godwin;C Willman;T Norwood;H Erba;D Howard;S Coutre;M Othus;F Appelbaum J Clin Oncol 30 (suppl; abstr 6502); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;

A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC0720568) as induction and post-remission therapy in patients of age 60 and older with previusly untreated non-M3 acute myeloid leukemia (SWOG S0703): Report on the poor risk patients

S Nand;M Othus;J Godwin;C Willman;TH Norwood;HP Erba;DS Howard;SE Coutre;F Appelbaum Blood 120(21):abst.3584; American Society of Hematology Annual Meeting, poster;